VolitionRx (NYSE:VNRX) Now Covered by Analysts at StockNews.com

Research analysts at StockNews.com initiated coverage on shares of VolitionRx (NYSE:VNRX) in a research report issued on Tuesday. The firm set a “sell” rating on the stock.

Other research analysts have also issued reports about the company. Benchmark reaffirmed a “hold” rating on shares of VolitionRx in a research report on Friday, November 22nd. D. Boral Capital reaffirmed a “buy” rating and issued a $5.00 target price on shares of VolitionRx in a research report on Thursday, February 6th.

VolitionRx Price Performance

VNRX opened at $0.58 on Tuesday. The stock has a market capitalization of $53.86 million, a price-to-earnings ratio of -1.61 and a beta of 1.20. VolitionRx has a 12 month low of $0.43 and a 12 month high of $1.10. The business has a 50-day moving average of $0.61 and a two-hundred day moving average of $0.65.

Insider Transactions at VolitionRx

In related news, Director Guy Archibald Innes acquired 174,764 shares of VolitionRx stock in a transaction that occurred on Monday, December 9th. The stock was acquired at an average price of $0.57 per share, for a total transaction of $99,615.48. Following the transaction, the director now directly owns 617,085 shares of the company’s stock, valued at $351,738.45. This trade represents a 39.51 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Cameron John Reynolds purchased 139,811 shares of VolitionRx stock in a transaction dated Monday, December 9th. The shares were purchased at an average cost of $0.57 per share, with a total value of $79,692.27. Following the acquisition, the chief executive officer now owns 2,117,404 shares of the company’s stock, valued at approximately $1,206,920.28. This trade represents a 7.07 % increase in their position. The disclosure for this purchase can be found here. Over the last 90 days, insiders have purchased 358,266 shares of company stock valued at $204,212. Insiders own 12.80% of the company’s stock.

Institutional Investors Weigh In On VolitionRx

Several large investors have recently made changes to their positions in VNRX. Millennium Management LLC acquired a new position in shares of VolitionRx during the fourth quarter valued at $36,000. Lagoda Investment Management L.P. raised its position in shares of VolitionRx by 24.3% during the 4th quarter. Lagoda Investment Management L.P. now owns 7,576,000 shares of the company’s stock worth $4,546,000 after buying an additional 1,481,000 shares in the last quarter. Northern Trust Corp lifted its stake in shares of VolitionRx by 32.0% in the 4th quarter. Northern Trust Corp now owns 117,875 shares of the company’s stock worth $71,000 after acquiring an additional 28,579 shares during the period. Two Sigma Securities LLC bought a new position in shares of VolitionRx in the fourth quarter valued at approximately $29,000. Finally, Geode Capital Management LLC increased its stake in shares of VolitionRx by 15.1% during the third quarter. Geode Capital Management LLC now owns 730,448 shares of the company’s stock valued at $439,000 after acquiring an additional 95,900 shares during the period. Institutional investors and hedge funds own 8.09% of the company’s stock.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.